Ovarian cancer

82 trials 42 recruiting MedDRA PT
82 Registered trials
42 Recruiting
61 Unique sponsors
76 Unique IMPs
68 Commercial trials
Drug classes (ATC)
— ATC code not specified 55
L Oncology (ATC L) 27
B Haematology (ATC B) 1
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 34 substances
Kinase inhibitor 7 substances
Antibody-drug conjugate (ADC) 5 substances
PARP inhibitor 5 substances
Antimetabolite 3 substances
Monoclonal antibody (tumor, humanized) 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Platinum compound 2 substances
Taxane 2 substances
Colony-stimulating factor 2 substances
Checkpoint inhibitor (PD-L1) 2 substances
Anthracycline 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (angiogenesis) 1 substance
Monoclonal antibody (unknown source) 1 substance
RAF/BRAF inhibitor 1 substance
BCL-2 inhibitor 1 substance
Alkylating agent 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
SERD 1 substance
CDK inhibitor 1 substance
Phase III: 13 Phase II/III: 1 Phase II: 23 Phase I/II: 6 Phase IV: 4 Phase I: 22 Phase I (Other): 6 Phase I (First in Human): 9

Filter these 82 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 82 trials

Phase III

13 trials
  • AGO Research GmbH Commercial
    BEVACIZUMAB; CARBOPLATIN; NIRAPARIB; NIRAPARIB TOSILATE MONOHYDRATE; PACLITAXEL
    2024-516066-11-00 4 countries 2022 n=1,103
    Recruiting
  • Amgen Inc. Commercial
    ROMIPLOSTIM
    2023-507149-27-00 5 countries 2019 n=46
    Recruiting
  • AstraZeneca AB Commercial
    OLAPARIB
    2024-512982-15-00 12 countries 2021 n=94
    Recruiting
  • Canariabio Inc. Commercial
    OREGOVOMAB
    2024-519218-30-00 5 countries 2021 n=64 Orphan
    Ended
  • Corcept Therapeutics Inc. Commercial
    PACLITAXEL ALBUMIN-BOUND; RELACORILANT
    2024-514080-25-00 6 countries 2023 n=205 Orphan
    Ended
  • Daiichi Sankyo Inc. Commercial
    BEVACIZUMAB; TRASTUZUMAB DERUXTECAN
    2024-516982-35-00 14 countries 2025 n=182
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIRAPARIB; PACLITAXEL; PEMETREXED; SUNITINIB; VEMURAFENIB; VENETOCLAX
    2023-506184-34-00 11 countries 2019 n=104 Orphan
    Ended
  • Genmab A/S Commercial
    RINATABART SESUTECAN
    2024-514822-21-00 12 countries 2025 n=171
    Recruiting
  • Incyte Corp. Commercial
    8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE; DOXORUBICIN HYDROCHLORIDE; INCB123667
    2025-522748-42-00 8 countries n=308
    Pending
  • Merck Sharp & Dohme LLC Commercial
    BEVACIZUMAB; SACITUZUMAB TIRUMOTECAN
    2023-508047-40-00 15 countries 2026 n=349
    Recruiting
  • Mural Oncology Inc. Commercial
    NEMVALEUKIN ALFA; PEMBROLIZUMAB
    2024-513230-38-00 10 countries 2022 n=244
    Ended
  • Tesaro Inc. Commercial
    IMP not specified
    2023-508010-42-00 12 countries 2016 n=469
    Ended
  • Karolinska University Hospital Academic
    IMP not specified
    2023-507732-20-00 1 country 2019 n=220
    Ended

Phase II/III

1 trial
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2023-507914-28-00 9 countries 2024 n=344
    Recruiting

Phase II

23 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    MIRVETUXIMAB SORAVTANSINE
    2025-521606-18-00 5 countries 2026 n=121
    Recruiting
  • Bayer Consumer Care AG Commercial
    3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE; BAY 2927088; SEVABERTINIB
    2024-517419-62-00 4 countries 2025 n=37
    Recruiting
  • Blue Earth Diagnostics Ireland Limited Commercial
    GA68-ONCOFAP
    2025-521983-36-00 2 countries n=65
    Pending
  • Bristol Myers Squibb International Corporation Commercial
    DOXORUBICIN HYDROCHLORIDE; FARLETUZUMAB ECTERIBULIN
    2023-504111-33-00 3 countries 2023 n=55
    Ended
  • Corcept Therapeutics Inc. Commercial
    RELACORILANT
    2024-517432-21-00 6 countries 2025 n=177 Orphan
    Recruiting
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2024-513307-13-00 5 countries 2025 n=73
    Ended
  • Dualitybio Inc. Commercial
    BNT324; BNT327; HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST TROP2 CONJUGATED TO N-((7S,15S)-7-BENZYL-17-(((1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL-10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12H-BENZO[DE]PYRANO[3',4':6,7] INDOLIZINO[1,2-B]QUINOLIN-1-YL)AMINO)-15-METHYL-2,5,8,11,17-PENTAOXO-14-OXA-3,6,9,12-TETRAAZAHEPTADECYL)-6-(2,5-DIOXO-2,5-DIHYDRO-1H-PYRROL-1-YL)HEXANAMIDE
    2025-523895-22-00 5 countries n=102
    Pending
  • Esperas Pharma Inc. Commercial
    GEMCITABINE; GEMCITABINE HYDROCHLORIDE; N-[5-(2-METHOXY-6-METHYLPYRIDIN-3-YL)-1H-PYRAZOL-3-YL]-6-[(3R)-PIPERIDIN-3-YL]OXYPYRAZIN-2-AMINE
    2023-503459-91-00 2 countries 2023 n=12
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    NIRAPARIB TOSILATE MONOHYDRATE
    2023-506618-29-00 6 countries 2021 n=10 Orphan
    Recruiting
  • Incyte Corp. Commercial
    8-ETHOXY-N-((3R,4S)-3-METHYL-1-(METHYLSULFONYL)PIPERIDIN-4-YL)-7-(1H-PYRAZOL-4-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-AMINE; INCB123667
    2025-521513-14-00 2 countries 2026 n=29
    Recruiting
  • Jazz Pharmaceuticals Ireland Limited Commercial
    ZANIDATAMAB
    2024-516551-41-00 1 country 2026 n=125
    Recruiting
  • Seagen Inc. Commercial
    DISITAMAB VEDOTIN
    2023-504445-31-00 4 countries 2024 n=28
    Recruiting
  • Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Commercial
    PEMBROLIZUMAB; SKB264
    2022-502654-14-00 4 countries 2023 n=101
    Recruiting
  • Tesaro Inc. Commercial
    BEVACIZUMAB; CARBOPLATIN; NIRAPARIB TOSILATE MONOHYDRATE; PACLITAXEL
    2023-505097-16-00 1 country 2022 n=15 Orphan
    Ended
  • Aalborg University Hospital Academic
    (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE; FLUDEOXYGLUCOSE (18F)
    2023-505938-98-00 1 country 2023 n=50
    Ended
  • AGO Research GmbH Academic
    DURVALUMAB; OLAPARIB
    2024-511780-28-00 1 country 2022 n=60
    Recruiting
  • Arcagy Gineco Academic
    BEVACIZUMAB; NIRAPARIB; NIRAPARIB TOSILATE MONOHYDRATE
    2023-504166-37-00 4 countries 2022 n=336
    Recruiting
  • Asso De Recherche Cancers Gynecologiques Academic
    MPS-112, MPS-106, MPS-213, MPS-102, MPS-216, MPS-103, MPS-215, MPS-214, D-ALA-LYS-CHA-VAL-ALA-ALA-TRP-THR-LEU-LYS-ALA-ALA-D-ALA, MPS-200; PEMBROLIZUMAB
    2024-516096-32-00 3 countries 2021 n=180
    Ended
  • IRCCS Istituto Nazionale Tumori Fondazione Pascale Academic
    OLAPARIB
    2024-516839-27-00 1 country 2024 n=200
    Recruiting
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    NIRAPARIB TOSILATE MONOHYDRATE
    2022-502559-69-01 6 countries 2024 n=640 Orphan
    Recruiting
  • Nordic Society Of Gynaecological Oncology Clinical Trial Unit Academic
    ALREFIMOTIDE, RILETAMOTIDE, TAPDERIMOTIDE; DURVALUMAB; OLAPARIB; SARGRAMOSTIM
    2024-516327-14-00 9 countries n=188 Orphan
    Pending
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-517363-24-00 1 country 2024 n=100
    Recruiting
  • Esperas Pharma Inc. Academic
    GEMCITABINE; GEMCITABINE HYDROCHLORIDE; N-[5-(2-METHOXY-6-METHYLPYRIDIN-3-YL)-1H-PYRAZOL-3-YL]-6-[(3R)-PIPERIDIN-3-YL]OXYPYRAZIN-2-AMINE
    2023-503459-91-00 2 countries 2023 n=12
    Ended

Phase I/II

6 trials
  • AstraZeneca AB Commercial
    SARUPARIB
    2024-519044-32-00 2 countries 2025 n=16
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    IPILIMUMAB; NIVOLUMAB
    2024-516540-25-00 1 country 2013 n=83
    Ended
  • Daiichi Sankyo Inc. Commercial
    IFINATAMAB DERUXTECAN
    2023-509632-26-00 9 countries 2025 n=311 Orphan
    Recruiting
  • Eisai Limited Commercial
    FARLETUZUMAB ECTERIBULIN; LENVATINIB
    2023-506868-14-00 2 countries 2023 n=90
    Ended
  • Kancera AB Commercial
    (2R)-2-[[2-AMINO-5-[(1S)-1-PHENYLETHYL]SULFANYL-[1,3]THIAZOLO[4,5-D]PYRIMIDIN-7-YL]AMINO]-4-METHYLPENTAN-1-OL HYDROCHLORIDE; CARBOPLATIN
    2024-515572-13-00 3 countries 2023 n=30
    Ended
  • Pfizer Inc. Commercial
    [(1R,3S)-3-[3-[[5-(METHOXYMETHYL)-2-METHYLPYRAZOLE-3-CARBONYL]AMINO]-1H-PYRAZOL-5-YL]CYCLOPENTYL]N-PROPAN-2-YLCARBAMATE MONOHYDRATE; FULVESTRANT; LETROZOLE; PALBOCICLIB
    2024-515492-34-00 1 country 2023 n=12
    Ended

Phase IV

4 trials
  • Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic
    CISPLATIN; PACLITAXEL
    2022-502691-23-00 1 country 2023 n=20
    Recruiting
  • Rita Fior Academic
    IMP not specified
    2023-509598-22-01 1 country 2025 n=276
    Recruiting
  • Uniwersytet Medyczny W Lublinie Academic
    IMP not specified
    2023-509659-15-00 1 country n=332
    Pending
  • Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic
    CISPLATIN; PACLITAXEL
    2022-502691-23-00 1 country 2023 n=20
    Recruiting

Phase I

22 trials
  • Amgen Inc. Commercial
    IMP not specified
    2022-502867-39-00 3 countries 2023 n=58
    Ended
  • Beigene Ltd. Commercial
    IMP not specified
    2023-505322-34-00 1 country 2024 n=45
    Ended
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
  • BeOne Medicines AG Commercial
    IMP not specified
    2025-523165-19-00 1 country 2026 n=15
    Recruiting
  • BioNTech Cell & Gene Therapies GmbH Commercial
    CLDN6 CAR-T; CLDN6 CAR-T(A); CLDN6 RNA-LPX; RBP030.2
    2024-514962-38-00 3 countries 2020 n=206
    Recruiting
  • Cullinan Therapeutics Inc. Commercial
    IMP not specified
    2024-511744-27-00 2 countries 2022 n=240
    Ended
  • Duke Street Bio Limited Commercial
    IMP not specified
    2023-508805-26-00 4 countries 2024 n=101
    Recruiting
  • Genentech Inc. Commercial
    IMP not specified
    2023-509266-38-00 2 countries n=23
    Pending
  • Ikena Oncology Inc. Commercial
    IMP not specified
    2022-502622-40-00 4 countries n=31
    Ended
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
  • Kancera AB Commercial
    IMP not specified
    2023-503909-11-00 1 country n=80
    Not authorised
  • Kancera AB Commercial
    IMP not specified
    2023-503909-11-01 1 country 2023 n=88
    Ended
  • Molecure S.A. Commercial
    IMP not specified
    2024-510836-31-00 1 country 2023 n=40
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Oncusp Therapeutics Inc. Commercial
    IMP not specified
    2024-519862-33-00 2 countries n=20
    Not authorised
  • Oncusp Therapeutics Inc. Commercial
    IMP not specified
    2024-519862-33-01 2 countries 2026 n=30
    Recruiting
  • Seagen Inc. Commercial
    SGN-ALPV
    2022-500094-14-00 3 countries 2022 n=82
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-508469-34-00 2 countries 2020 n=238
    Recruiting
  • Stemline Therapeutics Inc. Commercial
    IMP not specified
    2025-524168-39-00 1 country 2026 n=23
    Recruiting
  • Sutro Biopharma Inc. Commercial
    IMP not specified
    2024-513708-33-00 3 countries 2022 n=20
    Ended
  • Zymeworks Inc. Commercial
    IMP not specified
    2024-511119-11-00 1 country 2025 n=25
    Ended
  • Universitaetsklinikum Wuerzburg AöR Academic
    IMP not specified
    2024-512019-36-00 1 country 2025 n=44
    Recruiting

Phase I (Other)

6 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2025-522731-34-00 3 countries 2026 n=34
    Recruiting
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
  • Molecure S.A. Commercial
    IMP not specified
    2024-513006-61-00 1 country 2023 n=30
    Recruiting
  • Pfizer Inc. Commercial
    IMP not specified
    2024-518696-65-00 1 country 2025 n=9
    Ended
  • Toray Industries Inc. Commercial
    IMP not specified
    2024-513915-28-00 1 country 2019 n=32
    Ended
  • USWM Ct LLC Commercial
    IMP not specified
    2024-512864-71-00 1 country 2020 n=32
    Ended

Phase I (First in Human)

9 trials
  • AstraZeneca AB Commercial
    [11C]AZ14193391; 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL]-N-METHYLPYRIDINE-2-CARBOXAMIDE; DATOPOTAMAB DERUXTECAN; PALACAPARIB; TEMOZOLOMIDE; TRASTUZUMAB DERUXTECAN
    2023-504984-17-00 2 countries 2022 n=176
    Recruiting
  • BioNTech SE Commercial
    BNT142
    2024-512639-58-00 3 countries 2022 n=119
    Ended
  • Crescent Biopharma Inc. Commercial
    CR-001
    2025-523590-42-00 1 country n=44
    Pending
  • Daiichi Sankyo Inc. Commercial
    DS-3939A
    2023-507937-14-00 3 countries 2025 n=207
    Recruiting
  • Pmv Pharmaceuticals Inc. Commercial
    PC14586
    2023-504251-27-00 4 countries 2024 n=105
    Recruiting
  • Salubris Biotherapeutics Inc. Commercial
    JK08; LENVATINIB; PEMBROLIZUMAB
    2024-511750-53-00 2 countries 2022 n=130
    Ended
  • Scorpion Therapeutics Inc. Commercial
    IMP not specified
    2023-504807-94-00 7 countries 2023 n=178
    Recruiting
  • Theolytics Limited Commercial
    THEO-260
    2024-511236-27-00 1 country 2025 n=10
    Recruiting
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    IMP not specified
    2022-501910-79-01 1 country 2024 n=73
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Daiichi Sankyo Inc. Commercial 5 Phase II/III, Phase II, Phase III, Phase I (First in Human), Phase I/II 4
AstraZeneca AB Commercial 4 Phase I (Other), Phase III, Phase I (First in Human), Phase I/II 3
Kancera AB Commercial 3 Phase I, Phase I/II 0
Seagen Inc. Commercial 3 Phase I, Phase II 2
Amgen Inc. Commercial 2 Phase I, Phase III 1
BeOne Medicines AG Commercial 2 Phase I 2
Molecure S.A. Commercial 2 Phase I, Phase I (Other) 2
Oncusp Therapeutics Inc. Commercial 2 Phase I 1
Pfizer Inc. Commercial 2 Phase I (Other), Phase I/II 0
Bristol Myers Squibb International Corporation Commercial 2 Phase II, Phase I/II 0
Corcept Therapeutics Inc. Commercial 2 Phase II, Phase III 1
Esperas Pharma Inc. Commercial 2 Phase II 0
Incyte Corp. Commercial 2 Phase II, Phase III 1
Tesaro Inc. Commercial 2 Phase II, Phase III 0
AGO Research GmbH Commercial 2 Phase III, Phase II 2
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic 2 Phase IV 2
Beigene Ltd. Commercial 1 Phase I 0
BioNTech Cell & Gene Therapies GmbH Commercial 1 Phase I 1
Cullinan Therapeutics Inc. Commercial 1 Phase I 0
Duke Street Bio Limited Commercial 1 Phase I 1
New trials by year
2019
4
2020
3
2021
4
2022
11
2023
16
2024
12
2025
13
2026
8
← All indication landscapes